Mon, Sep 22, 2014, 8:30 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Linn Energy, LLC (LINE) Message Board

false 5 posts  |  Last Activity: Sep 15, 2014 1:12 PM Member since: Jul 16, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    MVIS stock price being manipulated

    by axel_nose Mar 31, 2008 4:07 PM
    false false Sep 15, 2014 1:12 PM Flag

    "This company's stock price should be %2

  • In speaking to Jim Fanucchi the other day, two things became obvious which I find disturbing.

    1) Jim related that reporting in Non GAAP was the industry norm. Well Avi I have news for you, Non-GAAP is bad. Non-GAAP means that GIG is making enough money to be an on going entity indefinitely; however it also means that each and every shareholder is losing money through dilution. That includes you Avi. Those 2+ million shares will only continue to drop in value as long as you continue to take big bonuses which push GIG out of GAAP profits. Non-GAAP also means that GIG's shares are valued far below where they should be which kills us every time you do a merger. Looking at past earning reports, it appears that every time GIG is close to making a GAAP profit, you Avi decide to take a big share bonus and continue the Non-GAAP smoothing. Heck the only time we had a GAAP profit, you took a big share bonus for a legal win. What the heck was that about? What twisted your mind into thinking you earned a bonus for that? So, here is a news flash Avi. You can continue to think in Non-GAAP and perhaps down the road you will have 4 million shares in a company worth less than $1 per share. Or you can start thinking in nothing less than GAAP earnings is acceptable and have 2 + million shares in a company worth over $10 a share.

    2) Big share bonuses for CEO's in the industry is the norm. Well Jim also pointed out that poor share performance as also the industry norm. Perhaps that means thinking and acting to achieve industry nor

  • PRESS RELEASE
    Aug. 10, 2014, 9:01 a.m. EDT
    CEL-SCI Corporation Reports Third Quarter Fiscal 2014 Financial Results


    VIENNA, Va., Aug 10, 2014 (BUSINESS WIRE) -- CEL-SCI Corporation (nyse mkt:CVM) today reported financial results for the quarter ended June 30, 2014.

    Recent key corporate and clinical developments include:

    Enrolled 54 patients in the Company’s Phase III head and neck cancer trial during the quarter, a 93% increase in sequential quarterly patient enrollment; Subsequently in July, achieved milestone of total 232 patients enrolled to date, representing over one-quarter of the total enrollment for the study.

    Added four clinical sites in the U.S. and additional clinical centers around the world for Multikine, an investigational immunotherapy being studied in a global pivotal Phase III head and neck cancer trial .

    Expanded the Phase III head and neck cancer trial into the United Kingdom during the quarter, with additional expansions post-quarter into Austria, Sri Lanka, Turkey and France.

    Raised approximately $9.84 million in net proceeds through the sale of common stock and warrants in a public offering and from the exercise of previously issued and outstanding warrants.

    CEL-SCI reported an operating loss of ($6,901,329) for the quarter ended June 30, 2014 versus an operating loss of ($5,513,199) for the quarter ended June 30, 2013. The operating loss for the nine months ended June 30, 2014 was ($19,062,074) versus ($14,796,535) during the nine months ended June 30, 2013. The rise in operating loss was mostly attributable to an increase in research and development expenses to $12,627,269 in the nine month ended June 30, 2014 compared to $9,208,900 in the nine months ended June 30, 2013. R&D expenses increased because of the expansion of the Company’s Phase III clinical study for head and neck cancer and an associated increase in patient enrollment.

    CEL-SCI's net loss available to common shareholders for the quarter ended June 30, 2014 was ($2,444,480) or ($0.04) per basic share, versus ($4,507,074) or ($0.15) per basic share during the quarter ended June 30, 2013. The net loss available to common shareholders for the nine months ended June 30, 2014 was ($21,261,925) or ($0.38) per basic share, versus ($7,530,621) or ($0.25) per basic share during the same nine months ended June 30, 2013. The increase in net loss for the three and nine month periods of 2014 as compared to the same periods in 2013 was primarily attributable to a non-cash charge for the change in value of derivative instruments caused by the fluctuation in the Company’s common stock share price.

    During the nine months ended June 30, 2014, the Company raised approximately $31.5 million in net proceeds through the sale of common stock and warrants in a public offering and from the exercise of previously issued and outstanding warrants.

    “We enrolled 54 patients in our Phase III head and neck cancer trial for the quarter ended June 30, 2014 which was the best quarter ever for us. Since the end of June, we have added four countries to%2

  • Reply to

    hey Foreman, greg_martin, isthislega1 ……...

    by casecard64 Jul 30, 2014 6:31 PM
    false false Jul 30, 2014 8:20 PM Flag

    Sorry, I'm just a private investor trying to warn new investors of the%2

  • You never see any insider buying in this company. They issue more stock for staff and dilutes the share base and insiders selling the stock on regular basis. It certainly makes you wonder when%2

LINE
30.39-0.79(-2.53%)Sep 22 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.